Overview
![]()
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb¿ platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is an international company with operations in Denmark, The Netherlands, and Princeton, New Jersey, USA.
Genmab has assembled pre-clinical and clinical teams with high levels of skill and experience and has established a streamlined process to coordinate the activities of product discovery, manufacturing, pre-clinical testing, clinical trial design, data management and regulatory submissions.
"One of the great strengths of Genmab is the teamwork and cooperation of our personnel, which helps us meet our goals and work in a dedicated fashion toward success for our shareholders," said Lisa N. Drakeman, Ph.D., Genmab's Chief Executive Officer.
|
Find a job, post your resume, research careers at featured companies, compare salaries and get career advice on Yahoo! HotJobs. Start your job search now on Yahoo! HotJobs - thousands of jobs listed daily.